Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OKYO vs LNTH vs NVCR vs MDT vs ISRG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OKYO
OKYO Pharma Limited

Biotechnology

HealthcareNASDAQ • GB
Market Cap$66M
5Y Perf.-20.5%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$6.06B
5Y Perf.+35.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-77.7%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$97.62B
5Y Perf.-24.0%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+97.7%

OKYO vs LNTH vs NVCR vs MDT vs ISRG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OKYO logoOKYO
LNTH logoLNTH
NVCR logoNVCR
MDT logoMDT
ISRG logoISRG
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & Supplies
Market Cap$66M$6.06B$2.04B$97.62B$159.85B
Revenue (TTM)$0.00$1.55B$674M$35.48B$10.58B
Net Income (TTM)$-5M$279M$-173M$4.61B$2.98B
Gross Margin60.5%75.2%61.9%66.3%
Operating Margin18.8%-27.2%17.9%30.5%
Forward P/E17.7x13.8x43.3x
Total Debt$0.00$738K$290M$28.52B$303M
Cash & Equiv.$2M$359M$103M$2.22B$3.37B

OKYO vs LNTH vs NVCR vs MDT vs ISRGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OKYO
LNTH
NVCR
MDT
ISRG
StockMay 22May 26Return
OKYO Pharma Limited (OKYO)10079.5-20.5%
Lantheus Holdings, … (LNTH)100135.8+35.8%
NovoCure Limited (NVCR)10022.3-77.7%
Medtronic plc (MDT)10076.0-24.0%
Intuitive Surgical,… (ISRG)100197.7+97.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: OKYO vs LNTH vs NVCR vs MDT vs ISRG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. LNTH also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Healthcare Pick

OKYO lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.

  • 42.9% 10Y total return vs ISRG's 5.5%
  • Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
  • +15.7% vs ISRG's -16.4%
Best for: long-term compounding and sleep-well-at-night
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 36 yrs, beta 0.42, yield 3.7%
  • Beta 0.42, yield 3.7%, current ratio 1.85x
  • Better valuation composite
  • Beta 0.42 vs NVCR's 2.15, lower leverage
Best for: income & stability and defensive
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • PEG 1.99 vs MDT's 35.17
  • 20.5% revenue growth vs OKYO's -11K%
  • 28.2% margin vs NVCR's -25.7%
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs OKYO's -11K%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs NVCR's -25.7%
Stability / SafetyMDT logoMDTBeta 0.42 vs NVCR's 2.15, lower leverage
DividendsMDT logoMDT3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)LNTH logoLNTH+15.7% vs ISRG's -16.4%
Efficiency (ROA)MDT logoMDT175.8% ROA vs OKYO's -128.4%

OKYO vs LNTH vs NVCR vs MDT vs ISRG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OKYOOKYO Pharma Limited

Segment breakdown not available.

LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
NVCRNovoCure Limited

Segment breakdown not available.

MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B

OKYO vs LNTH vs NVCR vs MDT vs ISRG — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

MDT and OKYO operate at a comparable scale, with $35.5B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
RevenueTrailing 12 months$0$1.5B$674M$35.5B$10.6B
EBITDAEarnings before interest/tax-$4M$347M-$165M$9.4B$3.8B
Net IncomeAfter-tax profit-$5M$279M-$173M$4.6B$3.0B
Free Cash FlowCash after capex-$2M$372M-$48M$5.4B$2.8B
Gross MarginGross profit ÷ Revenue+60.5%+75.2%+61.9%+66.3%
Operating MarginEBIT ÷ Revenue+18.8%-27.2%+17.9%+30.5%
Net MarginNet income ÷ Revenue+18.0%-25.7%+13.0%+28.2%
FCF MarginFCF ÷ Revenue+24.0%-7.1%+15.2%+26.8%
Rev. Growth (YoY)Latest quarter vs prior year+1.2%+12.3%+8.8%+23.0%
EPS Growth (YoY)Latest quarter vs prior year+83.3%+76.5%-100.0%-11.9%+18.8%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 4 of 7 comparable metrics.

At 21.1x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.63x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
Market CapShares × price$66M$6.1B$2.0B$97.6B$159.8B
Enterprise ValueMkt cap + debt − cash$65M$5.7B$2.2B$123.9B$156.8B
Trailing P/EPrice ÷ TTM EPS-13.58x27.29x-14.66x21.09x57.19x
Forward P/EPrice ÷ next-FY EPS est.17.70x13.80x43.35x
PEG RatioP/E ÷ EPS growth rate35.17x2.63x
EV / EBITDAEnterprise value multiple14.96x14.06x43.28x
Price / SalesMarket cap ÷ Revenue3.93x3.11x2.91x15.88x
Price / BookPrice ÷ Book value/share5.84x5.86x2.04x9.10x
Price / FCFMarket cap ÷ FCF17.11x18.83x64.18x
MDT leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 5 of 9 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-51 for NVCR. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs OKYO's 3/9, reflecting solid financial health.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
ROE (TTM)Return on equity+24.3%-50.8%+9.4%+16.9%
ROA (TTM)Return on assets-128.4%+12.4%-16.5%+175.8%+14.8%
ROICReturn on invested capital+30.6%-16.4%+6.0%+15.0%
ROCEReturn on capital employed+17.1%-28.9%+7.5%+16.5%
Piotroski ScoreFundamental quality 0–935566
Debt / EquityFinancial leverage0.00x0.85x0.59x0.02x
Net DebtTotal debt minus cash-$2M-$358M$187M$26.3B-$3.1B
Cash & Equiv.Liquid assets$2M$359M$103M$2.2B$3.4B
Total DebtShort + long-term debt$0$738,000$290M$28.5B$303M
Interest CoverageEBIT ÷ Interest expense-8.03x15.83x-96.80x9.08x
LNTH leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, LNTH leads with a +15.7% total return vs ISRG's -16.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs NVCR's -36.4% — a key indicator of consistent wealth creation.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
YTD ReturnYear-to-date-26.9%+38.3%+36.4%-20.0%-19.9%
1-Year ReturnPast 12 months+10.1%+15.7%+2.6%-5.5%-16.4%
3-Year ReturnCumulative with dividends-23.5%-1.9%-74.2%-6.3%+48.5%
5-Year ReturnCumulative with dividends-55.0%+338.1%-90.2%-29.2%+61.7%
10-Year ReturnCumulative with dividends-55.0%+4289.6%+38.5%+24.3%+549.2%
CAGR (3Y)Annualised 3-year return-8.5%-0.6%-36.4%-2.1%+14.1%
LNTH leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs OKYO's 48.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
Beta (5Y)Sensitivity to S&P 5000.98x0.45x2.15x0.42x1.00x
52-Week HighHighest price in past year$3.35$94.86$20.06$106.33$603.88
52-Week LowLowest price in past year$1.32$47.25$9.82$75.91$427.84
% of 52W HighCurrent price vs 52-week peak+48.7%+98.1%+89.2%+71.6%+74.5%
RSI (14)Momentum oscillator 0–10050.269.970.929.243.6
Avg Volume (50D)Average daily shares traded93K872K1.4M7.9M1.8M
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: LNTH as "Buy", NVCR as "Buy", MDT as "Buy", ISRG as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 6.7% for LNTH (target: $99). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.

MetricOKYO logoOKYOOKYO Pharma Limit…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plcISRG logoISRGIntuitive Surgica…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$99.25$33.50$109.50$622.60
# AnalystsCovering analysts17154955
Dividend YieldAnnual dividend ÷ price+3.7%
Dividend StreakConsecutive years of raises1036
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.0%0.0%+3.3%+1.4%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). LNTH leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 2 of 6 categories
Loading custom metrics...

OKYO vs LNTH vs NVCR vs MDT vs ISRG: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OKYO or LNTH or NVCR or MDT or ISRG a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OKYO or LNTH or NVCR or MDT or ISRG?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 1. 99x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — OKYO or LNTH or NVCR or MDT or ISRG?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus OKYO's -55. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OKYO or LNTH or NVCR or MDT or ISRG?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 406% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — OKYO or LNTH or NVCR or MDT or ISRG?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OKYO or LNTH or NVCR or MDT or ISRG?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OKYO or LNTH or NVCR or MDT or ISRG more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 1. 99x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 29. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

08

Which pays a better dividend — OKYO or LNTH or NVCR or MDT or ISRG?

In this comparison, MDT (3.

7% yield) pays a dividend. OKYO, LNTH, NVCR, ISRG do not pay a meaningful dividend and should not be held primarily for income.

09

Is OKYO or LNTH or NVCR or MDT or ISRG better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OKYO and LNTH and NVCR and MDT and ISRG?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OKYO is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ISRG is a mid-cap high-growth stock. MDT pays a dividend while OKYO, LNTH, NVCR, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OKYO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.